Beware The Ides of March? AnaptysBio's Imsidolimab Has Another Trial Failure

 
• By Alaric DeArment
AnaptysBio may have a better shot at a rarer skin condition with imsidolimab after acne trial failure • Source: Shutterstock

More from Dermatological

More from Therapeutic Category